SOURCE: Avant Diagnostics, Inc.

Avant Diagnostics, Inc. Logo

December 15, 2015 09:30 ET

Avant Diagnostics, Inc. Announces Launch of New Corporate Website

The New Website Showcases the Company's Products and Vision in User-Friendly Platform for Customers and Investors while Maximizing Corporate Transparency

SCOTTSDALE, AZ--(Marketwired - December 15, 2015) - Avant Diagnostics, Inc. (OTCQB: AVDX), "Avant", unveiled its new website on December 12, 2015. The site, avantdiagnostics.com, incorporates numerous features to make browsing a more streamlined and informative experience for the Company's current and potential customers and investors. Major features of the new site include imagery, look, branding and content.

The Investor Relations section of the new website features immediate posting of the Company's press releases as they are issued, as well as the automated posting of SEC filings, XBRL data, Insider Section 16 filings and detailed annual as well as quarterly financial statements. Stock information data such as quotes, charts and historical prices are updated on demand with a 20-minute delay and the Company's financial tear sheet is updated daily after the market close. There is also an IR calendar featuring upcoming events, conference calls, investor presentations, CEO interviews and media coverage as well as corporate videos and an up-to-date frequently asked question section.

Gregg Linn, President and Chief Executive Officer of Avant, said, "A significant part of Avant's mission is presenting those interested in the company with the information they want in the quickest and most organized way. We believe our new website advances this goal by presenting our range of services and activities in an attractive and easy-to-access format. As our official online portal, it accurately reflects the variety and excitement of what we have to offer to those with whom we do business."

Mr. Linn continued, "A major goal for the new website is to maximize Avant's level of corporate transparency for the benefit of its customers and investors, and we are confident that the new website succeeds in furthering this transparency. Furthermore, the website allows us to archive an extensive range of corporate materials and information that can be easily searched and accessed by any user at any time." 

Avant engaged Equisolve, Inc. to design, develop and provide ongoing management for the new website. Equisolve is the leading company delivering cutting edge communications solutions for public companies by integrating the company's corporate website and IR website on a single platform.

Make sure you are first to receive timely information on Avant when it hits the newswire. Sign up for Avant email news alert system today at: www.avantdiagnostics.com.

About Avant Diagnostics, Inc.

Avant is a medical diagnostic technology company that specializes in large panel biomarker tests. Our first test, OvaDx®, is proposed for use in monitoring women diagnosed previously with ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA 510(k) clearance, Avant intends to sell or license OvaDx®. Avant intends to utilize its public company stage to expand its portfolio of diagnostic tests in the future.

Safe Harbor Statement

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Avant's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Avant does not undertake an obligation to update or revise any forward-looking statement except as required by law. Investors should read the risk factors set forth in Avant's Form 8-K filed with the Securities and Exchange Commission on January 14, 2015, as amended on January 16, 2015, and other periodic reports filed with the Securities and Exchange Commission.

Contact Information